Sabarubicin Hydrochloride

盐酸莎巴比星

Report date: 2023/04/21 17:59:49
NME

Base Information

Drug NameSabarubicin Hydrochloride
Drug Alias NameSabarubicina盐酸沙柔比星莎巴比星SabarubicineSabarubicinum +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovotek Therapeutics IncMenarini
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHefei Cosource PharmaceuticalsNovotek Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A